Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study
  • This current data set is from the second part of Algernon’s in vitro experiment designed to focus on duration of infusion needed to achieve maximal cortical neuron outgrowth
  • The final data set from the study is expected to be completed by the end of November 2021
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share

Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study.

The study, conducted by Charles River Laboratories, also confirms that the increased growth was achieved with a sub-hallucinogenic dose.

This current data set is from the second part of Algernon’s in vitro experiment designed to focus on the duration of infusion needed to achieve maximal cortical neuron outgrowth.

Chris Moreau, CEO of Algernon Pharmaceuticals spoke with Caroline Egan to discuss the news.

The data showed that an increase in growth of over 40 per cent was observed in the group treated for 6 hours with 30 nM DMT when compared to control. The results from the 6-hour period were superior to other treatment time periods and doses.

The final data set from the study will focus on investigating the mechanisms related to DMT which may be causing the growth of the neurons and is expected to be completed by the end of November 2021.

Algernon has established a clinical research program for the treatment of stroke focused on DMT, a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin).

Algernon has also filed new provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and Constraint-Induced Movement Therapy (“CIMT”).

Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.08 per share.

More From The Market Herald
The Market Herald Video

" LUXXFOLIO Holdings (CSE:LUXX) provides operational update

LUXXFOLIO Holdings’ (LUXX) November updates includes record mining revenues of approximately $1.8 million and monthly rewards of 23.5 Bitcoin.
LexaGene - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) closes multiple MiQLab sales

LexaGene (LXG) has received purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
The Market Herald Video

" FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.